Eikon Therapeutics
Business Services · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
3929 Point Eden Way, Hayward, California...Phone Number
(341) 777-0566Website
www.eikontx.comRevenue
$63.4 MillionIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
4
4
2
2
2
About Eikon Therapeutics
Eikon Therapeutics, founded in 2019, is a private biotechnology company headquartered in Hayward, California. Specializing in integrating advanced engineering with molecular and cell biology, Eikon aims to accelerate drug discovery and development.Explore more
Eikon Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eikon Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Eikon Therapeutics is spiking on competitors!
Product Launch: Get notified when Eikon Therapeutics launches new products
Funding: Get notified immidiatlly once Eikon Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Eikon Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Eikon Therapeutics had a recent Job posting/layoffs
Check if Eikon Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Eikon Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Eikon Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Eikon Therapeutics
Find more new buyers
Compare Similar Companies to Eikon Therapeutics
Compare insights from companies similar to Eikon Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Eikon Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Eikon Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Eikon Therapeutics.
Eikon Therapeutics financials insights
Gather financial insights about Eikon Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$148M
2022
Series B
$517.8M
2023
Series C
$106M
2025
Series D
$351M
2026
IPO
$381.2M
Eikon Therapeutics Tech Stack
A closer look at the technologies used by Eikon Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Earnings, Finance
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Open Position
Eikon Therapeutics News & Media
Eikon Therapeutics to Join the Russell 3000® Index
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment communityEikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ma. Fatima ("Fama") D. Francisco as an independent director to Eikon’s Board of Directors, effective June 15, 2026. Ms. Francisco will also serve on the Compensation Committee of the Board.Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations on several of its lead programs at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, including updated data for its EIK1001 trial in non-small cell lung cancer (NSCLC) and its highly selective PARP1 inhibitEikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
The six accepted presentations highlight clinical progress across Eikon’s pipeline.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eikon Therapeutics
Sign Up For FreeTo access detailed company insights
Eikon Therapeutics, founded in 2019, is a private biotechnology company headquartered in Hayward, California. Specializing in integrating advanced engineering with molecular and cell biology, Eikon aims to accelerate drug discovery and development.... Read More
